A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models

PloS One
Hao ZhangHyung L Kim


Rapamycin analogs, temsirolimus and everolimus, are approved for the treatment of advance renal cell carcinoma (RCC). Currently approved agents inhibit mechanistic target of rapamycin (mTOR) complex 1 (mTORC1). However, the mTOR kinase exists in two distinct multiprotein complexes, mTORC1 and mTORC2, and both complexes may be critical regulators of cell metabolism, growth and proliferation. Furthermore, it has been proposed that drug resistance develops due to compensatory activation of mTORC2 signaling during treatment with temsirolimus or everolimus. We evaluated Ku0063794, which is a small molecule that inhibits both mTOR complexes. Ku0063794 was compared to temsirolimus in preclinical models for renal cell carcinoma. Ku0063794 was effective in inhibiting the phosphorylation of signaling proteins downstream of both mTORC1 and mTORC2, including p70 S6K, 4E-BP1 and Akt. Ku0063794 was more effective than temsirolimus in decreasing the viability and growth of RCC cell lines, Caki-1 and 786-O, in vitro by inducing cell cycle arrest and autophagy, but not apoptosis. However, in a xenograft model there was no difference in the inhibition of tumor growth by Ku0063794 or temsirolimus. A potential explanation is that temsirolimus has ...Continue Reading


Feb 3, 1995·The Journal of Biological Chemistry·E F BlommaartA J Meijer
Jan 27, 2000·The Journal of Urology·Robert J Motzer, P Russo
Apr 20, 2001·Proceedings of the National Academy of Sciences of the United States of America·V G TusherG Chu
Dec 24, 2003·PLoS Biology·Keiichi KondoWilliam G Kaelin
Oct 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Manuel HidalgoEric K Rowinsky
Jan 9, 2007·Current Opinion in Genetics & Development·John D Gordan, M Celeste Simon
Jun 1, 2007·The New England Journal of Medicine·Gary R HudesGlobal ARCC Trial
Jul 3, 2007·Cell·Brendan D Manning, Lewis C Cantley
Jul 6, 2007·Autophagy·Noboru Mizushima, Tamotsu Yoshimori
Sep 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerJanice P Dutcher
Dec 21, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John G KuhnNorth American Brain Tumor Consortium and the National Cancer Institute
Oct 24, 2008·The Journal of Biological Chemistry·Alfredo ToschiDavid A Foster
Feb 13, 2009·PLoS Biology·Morris E FeldmanKevan M Shokat
Mar 10, 2009·Lancet·Brian I RiniBernard Escudier
May 1, 2009·The Biochemical Journal·Juan M García-MartínezDario R Alessi
Oct 3, 2009·The Lancet Oncology·Brian I Rini, Michael B Atkins
Dec 2, 2009·Clinical Journal of Oncology Nursing·Laura S Wood
Dec 17, 2009·Current Opinion in Cell Biology·Thomas P Neufeld
Dec 17, 2009·Journal of Biomolecular Screening·Sean T GlennHyung L Kim
Jan 15, 2010·Nature Medicine·Matthew R JanesDavid A Fruman
Mar 17, 2010·The Journal of Biological Chemistry·Kathryn G Foster, Diane C Fingar
Apr 13, 2010·The Lancet Oncology·Kyle A FurgeBin T Teh
May 8, 2010·Nature Reviews. Urology·W Marston LinehanLaura S Schmidt
Jul 8, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniel C ChoJames W Mier
Jul 14, 2010·Drug Discovery Today. Therapeutic Strategies·Qingsong LiuNathanael S Gray
Dec 16, 2010·Nature Reviews. Molecular Cell Biology·Roberto ZoncuDavid M Sabatini


May 7, 2013·Antioxidants & Redox Signaling·Zhibo Wang, Mary E Choi
May 8, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Sentai DingKejia Ding
Jun 17, 2015·Leukemia & Lymphoma·Shahab Uddin, Ramzi M Mohammad
Aug 30, 2013·Expert Opinion on Pharmacotherapy·Edwin M PosadasRobert A Figlin
Oct 16, 2015·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Ayunadirah AyubHeng Fong Seow
Mar 12, 2015·Future Oncology·Anna M CzarneckaCezary Szczylik
Aug 2, 2016·Nature Reviews. Nephrology·Daniel FantusAngus W Thomson
May 26, 2017·Expert Opinion on Therapeutic Targets·Yoko TabeMarina Konopleva
Mar 7, 2014·PloS One·Wilhelmina C M DuivenvoordenJehonathan H Pinthus
Mar 20, 2018·PloS One·Alberto BrescianiAndreas Weiss
Jan 31, 2016·Journal of Cell Science·Kiyomi Tsuji-Tamura, Minetaro Ogawa
Mar 9, 2019·Biomolecules·Giovanna AntonaciSanto Marsigliante
May 29, 2019·The Cancer Journal·Kira L RussellMichael T Lotze
Jan 8, 2014·Oncotarget·Maria Giovanna Francipane, Eric Lagasse
Jun 23, 2018·Brain : a Journal of Neurology·Jessica AgostinoneAdriana Di Polo
Apr 6, 2019·Frontiers in Chemistry·Marcus J C LongYimon Aye
Aug 22, 2015·PloS One·Maikel A FarhanAllan G Murray
Mar 25, 2019·Experimental and Therapeutic Medicine·Qiuyue LiJing Zhou
Jul 12, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Qi Wen FanWilliam A Weiss
Dec 17, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tatiana ErazoJose M Lizcano

Methods Mentioned

Protein Assay
flow cytometry

Related Concepts

EIF4EBP1 protein, human
CCI 779
Ku 0063794
MTORC1 complex, rat
TOR complex 2
Chromophobe Renal Cell Carcinoma
Pathologic Neovascularization

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.


Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Autophagy & Metabolism

Autophagy preserves the health of cells and tissues by replacing outdated and damaged cellular components with fresh ones. In starvation, it provides an internal source of nutrients for energy generation and, thus, survival. A powerful promoter of metabolic homeostasis at both the cellular and whole-animal level, autophagy prevents degenerative diseases. It does have a downside, however--cancer cells exploit it to survive in nutrient-poor tumors.

Autophagy & Model Organisms

Autophagy is a cellular process that allows degradation by the lysosome of cytoplasmic components such as proteins or organelles. Here is the latest research on autophagy & model organisms

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Autophagy & Disease

Autophagy is an important cellular process for normal physiology and both elevated and decreased levels of autophagy are associated with disease. Here is the latest research.

Parkinson's Disease & Autophagy (MDS)

Autophagy leads to degradation of damaged proteins and organelles by the lysosome. Impaired autophagy has been implicated in several diseases. Here is the role of autophagy in Parkinson’s disease.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.